An extended terminal half-life for darbepoetin alfa: Results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis

Clinical Pharmacokinetics

Volumn 45, Issue 5, 2006, Pages 503-510

  Padhi, Desmond ^a   Ni, Liyun ^a   Cooke, Blaire ^a   Marino, Rafael ^a   Jang, Graham ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; BLOOD SAMPLING; CALCULATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL CHEMISTRY; CLINICAL TRIAL; COUGHING; DIARRHEA; DISEASE EXACERBATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; GOUT; HEMODIALYSIS; HUMAN; HYPOTHESIS; LABORATORY TEST; LEG EDEMA; MALE; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; URINARY TRACT INFECTION;

ADULT; AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; HALF-LIFE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 33646132045     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645050-00005     Document Type: Article

References (27)

1. Kazmi WH, Kausz AT, Khan SS, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001; 38: 803-12
2. Obrador GT, Pereira BJ. Anaemia of chronic kidney disease: an under-recognized and under-treated problem. Nephrol Dial Transplant 2002; 17 Suppl. 11: 44-6
3. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501-10
4. Tong EM, Nissenson AR. Erythropoietin and anemia. Semin Nephrol 2001; 21: 190-203
5. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69
6. Khan SS, Kazmi WH, Abichandani R, et al. Health care utilization among patients with chronic kidney disease. Kidney Int 2002; 62: 229-36
7. Eprex solution for injection: summary of product characteristics [product information]. High Wycombe: Janssen-Cilag Ltd, 2004
8. Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000; 20: 375-81
9. Macdougall I. Optimizing the use of erythropoietic agents: pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002; 17 Suppl. 5: 66-70
10. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31: 290-9
11. Suranyi MG, Lindberg JS, Navarro J, et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003; 23: 106-11
12. Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004; 24: 453-60
13. Ling B, Walczyk M, Agarwal A, et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005; 63: 327-34
14. Aranesp® (darbepoetin alfa) prescribing information. Thousand Oaks (CA): Amgen Inc., 2002
15. Cases A. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Drugs Today (Barc) 2003; 39: 477-95
16. Aranesp (darbepoetin alfa): summary of product characteristics (annex I). Thousand Oaks (CA): Amgen Inc., 2004
17. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-5
18. Padhi D, Jang G. Pharmacokinetics (PK) of Aranesp (darbepoetin alfa) in patients with chronic kidney disease (CKD). 42nd European Renal Association-European Dialysis and Transing plant Association (ERA-EDTA) Congress; 2005 Jun 4-7; Istanbul
19. Kindler J, Eckardt KU, Ehmer B, et al. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol Dial Transplant 1989; 4: 345-9
20. Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 1991; 59: 399-402
21. Jensen JD, Madsen JK, Jensen LW, et al. Pharmacokinetics of erythropoietin in dialysis patients before and after correction of the anaemia. Drug Invest 1994; 8: 278-87
22. Macdougall IC, Roberts DE, Neubert P, et al. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989; I: 425-7
23. Boelaert JR, Schurgers ML, Matthys EG, et al. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 1989; 9: 95-8
24. Petersen J, Kang MS, Hays MT. Erythropoietin can be administered during dialysis: a kinetic analysis. ASAIO J 1996; 42: 27-33
25. Deicher R, Horl WH. Differentiating factors between erythropoiesis-stimulating agents. Drugs 2004; 64: 499-509
26. Sarac E, Veres Z, Tallam S, et al. Hemoglobin responses following de novo darbepoetin alfa (ARANESP®) versus epoetin alfa (PROCRIT®) administration in anemic chronic kidney disease patients [abstract]. American Society of Nephrology 37th Annual Meeting and Scientific Exposition; 2004 29 Oct-1 Nov; St Louis (MO)
27. Deray G. Achieving therapeutic targets in renal anaemia: considering cost-efficacy. Curr Med Res Opin 2004; 20: 1095-101